Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
- PMID: 33686287
- DOI: 10.1038/s41588-021-00805-2
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
Abstract
The ongoing COVID-19 pandemic has caused a global economic and health crisis. To identify host factors essential for coronavirus infection, we performed genome-wide functional genetic screens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus 229E. These screens uncovered virus-specific as well as shared host factors, including TMEM41B and PI3K type 3. We discovered that SARS-CoV-2 requires the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. TMEM106B overexpression enhanced SARS-CoV-2 infection as well as pseudovirus infection, suggesting a role in viral entry. Furthermore, single-cell RNA-sequencing of airway cells from patients with COVID-19 demonstrated that TMEM106B expression correlates with SARS-CoV-2 infection. The present study uncovered a collection of coronavirus host factors that may be exploited to develop drugs against SARS-CoV-2 infection or future zoonotic coronavirus outbreaks.
References
- 
    - Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).
 
- 
    - WHO Solidarity Trial Consortium et al. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2023184 (2020).
 
- 
    - Horby, P. et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
- Molecular Biology Databases
- Research Materials
- Miscellaneous
 
        